纳武利尤单抗联合伊匹木单抗两种给药方案在晚期黑色素瘤患者中的评估:IIIb/IV期CheckMate 511试验结果
CheckMate 511研究将360例初治不可切除III/IV期黑色素瘤患者随机分配至纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg(NIVO3+IPI1)组或纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg(NIVO1+IPI3)组,主要终点为治疗相关3-5级不良事件发生率。中位随访至少12个月时,NIVO3+IPI1组发生率为34%,NIVO1+IPI3组为48%(P=0.006)。描述性分析显示两组疗效终点无有意义的差异。
要点
- NIVO3+IPI1组治疗相关3-5级不良事件发生率为34%,NIVO1+IPI3组为48%(P=0.006)。
- 描述性分析中,NIVO3+IPI1组客观缓解率为45.6%,NIVO1+IPI3组为50.6%。
- NIVO3+IPI1组中位无进展生存期为9.9个月,NIVO1+IPI3组为8.9个月。
核心结论
- CheckMate 511研究达到主要终点,显示NIVO3+IPI1组治疗相关3-5级不良事件发生率显著低于NIVO1+IPI3组。
- 描述性分析显示两组各疗效终点均无有意义的差异,但更长的随访可能有助于更好地描述疗效结局。
研究设计与样本
- IIIb/IV期研究(CheckMate 511),纳入360例年龄18岁及以上、既往未经治疗、不可切除的III期或IV期黑色素瘤患者。
- 患者按1:1随机分配至NIVO3+IPI1组或NIVO1+IPI3组,每3周一次共4剂;6周后所有患者接受纳武利尤单抗480 mg每4周一次直至疾病进展或不可接受的毒性。
- 主要终点为组间治疗相关3-5级不良事件发生率的比较,次要终点包括客观缓解率、无进展生存期和总生存期的描述性分析。
- 研究未设计用于正式证明NIVO3+IPI1在疗效终点上非劣效于NIVO1+IPI3。
主要发现
- 中位随访至少12个月时,治疗相关3-5级不良事件发生率NIVO3+IPI1组为34%,NIVO1+IPI3组为48%(P=0.006)。
- 描述性分析中,客观缓解率NIVO3+IPI1组为45.6%,NIVO1+IPI3组为50.6%;完全缓解率分别为15.0%和13.5%。
- 中位无进展生存期NIVO3+IPI1组为9.9个月,NIVO1+IPI3组为8.9个月。
- 中位总生存期两组均未达到。
关键数值与推荐
- NIVO3+IPI1组治疗相关3-5级不良事件发生率为34%,NIVO1+IPI3组为48%(P=0.006)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究未设计用于正式证明NIVO3+IPI1在疗效终点上非劣效于NIVO1+IPI3。
- 描述性分析显示两组疗效终点无有意义的差异,但更长的随访可能有助于更好地描述疗效结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma in several countries. We conducted a phase IIIb/IV study (CheckMate 511) to determine if nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (NIVO3+IPI1) improves the safety profile of the combination. PATIENTS AND METHODS: Patients (N = 360) age 18 years or older with previously untreated, unresectable stage III or IV melanoma were randomly assigned 1:1 to NIVO3+IPI1 or NIVO1+IPI3 once every 3 weeks for four doses. After 6 weeks, all patients received NIVO 480 mg once every 4 weeks until disease progression or unacceptable toxicity. The primary end point was a comparison of the incidence of treatment-related grade 3 to 5 adverse events (AEs) between groups. Secondary end points included descriptive analyses of objective response rate, progression-free survival, and overall survival. The study was not designed to formally demonstrate noninferiority of NIVO3+IPI1 to NIVO1+IPI3 for efficacy end points. RESULTS: At a minimum follow-up of 12 months, incidence of treatment-related grade 3 to 5 AEs was 34% with NIVO3+IPI1 versus 48% with NIVO1+IPI3 ( P = .006). In descriptive analyses, objective response rate was 45.6% in the NIVO3+IPI1 group and 50.6% in the NIVO1+IPI3 group, with complete responses in 15.0% and 13.5% of patients, respectively. Median progression-free survival was 9.9 months in the NIVO3+IPI1 group and 8.9 months in the NIVO1+IPI3 group. Median overall survival was not reached in either group. CONCLUSION: The CheckMate 511 study met its primary end point, demonstrating a significantly lower incidence of treatment-related grade 3-5 AEs with NIVO3+IPI1 versus NIVO1+IPI3. Descriptive analyses showed that there were no meaningful differences between the groups for any efficacy end point, although longer follow up may help to better characterize efficacy outcomes.
引用
- Lebbé C, Meyer N, Mortier L, et al. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. J Clin Oncol. 2019. PMID: 30811280. doi:10.1200/JCO.18.01998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。